A Phase I Trial of Vascular-Targeted Photodynamic Therapy in Esophagogastric Cancer Patients With Moderate to Severe Dysphagia
Phase of Trial: Phase I
Latest Information Update: 09 Sep 2019
Price : $35 *
At a glance
- Drugs Padeliporfin (Primary)
- Indications Adenocarcinoma; Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions
- 09 Sep 2019 Last checked against ClinicalTrials.gov: US National Institutes of Health
- 04 Jun 2019 Planned number of patients changed from 36 to 30.
- 01 May 2019 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.